Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) revealed earnings for full year that Dropped, from the same period last year
The company's bottom line came in at RMB1.777 billion, or RMB1.93 per share. This compares with RMB2.531 billion, or RMB2.76 per share, last year.
The company's revenue for the period fell 22.4% to RMB6.218 billion from RMB8.016 billion last year.
Hubei Jumpcan Pharmaceutical Co., Ltd. earnings at a glance (GAAP) :
-Earnings: RMB1.777 Bln. vs. RMB2.531 Bln. last year.-EPS: RMB1.93 vs. RMB2.76 last year.-Revenue: RMB6.218 Bln vs. RMB8.016 Bln last year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.